Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.

IF 3.1 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2025-12-01 Epub Date: 2025-08-13 DOI:10.1007/s11060-025-05190-y

Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez, Bernardo Cacho-Díaz

{"title":"Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.","authors":"Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez, Bernardo Cacho-Díaz","doi":"10.1007/s11060-025-05190-y","DOIUrl":null,"url":null,"abstract":"Purpose: Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.Methods: A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.Results: From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.Conclusion: In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1227-1234"},"PeriodicalIF":3.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05190-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.

Methods: A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.

Results: From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.

Conclusion: In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.

查看原文本刊更多论文

中枢神经系统转移患者的真实体验结果：15年期间2226例患者的信息。

目的：大多数关于中枢神经系统（CNS）转移的数据来自临床试验中登记的非西班牙裔人群。本研究旨在描述西班牙裔/拉丁裔真实世界人群中发生中枢神经系统转移的原发肿瘤、初始治疗和结果。方法：对2010年至2024年接受治疗的中枢神经系统转移患者进行多中心队列回顾性分析。结果：在2261例中枢神经系统转移患者中，84%发生脑转移，16%发生肿瘤性脑膜炎。最常见的原发肿瘤是乳腺（40%）、肺（27%）、泌尿生殖系统（11%）、妇科（6%）和黑色素瘤（4%）。全脑放疗和全身治疗最初分别用于84%和55%的病例。中位总生存期为9.8个月（95% CI, 8.9 - 10.7）。与预后相关的变量包括原发肿瘤的位置、分子亚型、中枢神经系统转移类型（脑转移与肿瘤性脑膜炎）以及是否接受靶向治疗。结论：在一个真实世界的西班牙/拉丁裔CNS转移患者队列中，过去15年生存率仍然很低。这突出表明需要进行干预和研究以改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.